Canada markets closed

PureTech Health plc (PRTC)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
28.68-0.07 (-0.24%)
At close: 04:00PM EDT

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Dr. Bharatt M. Chowrira J.D., Ph.D.CEO & Executive Director2.19MN/A1965
Ms. Daphne ZoharFounder, Senior Advisor & Board Observer3.99MN/A1971
Dr. Robert S. Langer Jr., Ph.D.Co-Founder & Non-Executive Director135kN/A1949
Dr. Eric Elenko Ph.D.PresidentN/AN/A1973
Dr. David R. Elmaleh Ph.D.Co-Founder & Senior AdvisorN/AN/A1948
Mr. Eric Green M.B.A.Chief Operating OfficerN/AN/AN/A
Ms. Allison Mead TalbotHead of Communications & Investor RelationsN/AN/AN/A
Mr. Charles Sherwood III, J.D., Ph.D.General Counsel & Company SecretaryN/AN/AN/A
Mr. Spencer BallSenior Vice President of Human ResourcesN/AN/AN/A
Ms. Aleksandra Filipovic M.D., Ph.D.Head of OncologyN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.